Global Industry Overview - Biotech
Drug developers are capitalizing on the momentum within the biotechnology industry, driven by optimism fueled by corporate takeovers and a favorable market climate. Kyverna Therapeutics Inc. and Metagenomi Inc. are poised to be the fourth and fifth biotech companies to go public in 2024, following the success of three initial public offerings (IPOs) that collectively raised $786 million, marking the sector's strongest start since 2021.
The first three biotech IPOs of 2024 have demonstrated substantial gains, with ArriVent Biopharma Inc., Alto Neuroscience Inc., and CG Oncology Inc. experiencing share price increases ranging from 22% to 100% above their IPO prices. CG Oncology's significant rally, raising over $10 million, serves as an indication of investors' willingness to support companies with more advanced drug development stages.
A biotech exchange-traded fund has surged by 38% since October, propelled by major pharmaceutical companies like Novartis AG and Bristol Myers Squibb Co. engaging in significant takeovers. Industry experts anticipate a rise in venture capital-backed biotech IPOs, with a specific focus on later-stage companies and drugs presenting near-term catalyst opportunitie
Most Read
Other News
WHO cites Georgia’s Hepatitis C elimination program as a successful example
30.07.2026.18:13
The World Health Organization’s Regional Office for Europe (WHO/Europe) has cited Georgia’s Hepatitis C elimination program as a successful example, the Georgian Health Ministry said.
According to the Ministry, the WHO 2026 Global Report on Hepatitis emphasizes Georgia’s progress and experience in how a disease can be reduced through firm political will, large-scale testing, and the provision of universal treatment.
“Georgia’s Hepatitis C elimination program has demonstrated that elimination is not merely a goal, but a truly achievable outcome. By expanding testing, ensuring access to treatment, and collaborating closely with communities, we have dramatically reduced the burden of Hepatitis C in the country.
Our experience demonstrated that any country can make progress when Hepatitis elimination becomes a national priority,” said Maia Tsereteli, Head of Division of HIV/AIDS, Hepatitis, TB and STIs at the National Center for Disease Control and Public Health (NCDC).
The Health Ministry believes this international recognition highlights Georgia’s leadership in this direction.
The WHO calls on countries in the European region to overcome barriers and draw on the experience of successful nations to achieve the elimination of viral hepatitis by 2030.
Health Minister thanks parents for constructive talks, joint working group critically important to secure DMD medication
04.06.2026.17:52
Working group to be established on medicines for children with Duchenne muscular dystrophy - Georgian PM
04.06.2026.17:50
WHO Director-General: Georgia’s “commitment, success” gives us hope that malaria-free world “possible”
27.01.2025.00:00
